Developing CRISPR-based therapies to cure viral infectious diseases.
Excision develops CRISPR-based therapies to cure viral infectious diseases. The company’s first targeted viral infection is HIV, with a pipeline to begin trials on treatments for Herpes Simplex Virus, JC Virus/PML andHepatitis B in the next ~2-3 years.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
